1: Executive Summary
The Brain Industry Revealed
Neuropharmaceuticals
Neurodevices
Neurodiagnostics
Investment Risks and Opportunities
Translating Neuroscience into Neurotech
The Neurotech Market Opportunity
NASDAQ NeuroInsights Neurotech Index
Neurotechnology and Society
Key Industry Facts and Findings
Market Overview
Industry Overview
Venture Financing
Public Market Activity
Global Growth Drivers
Other Findings

2: Trends and Drivers
Converging Technology Drivers
Stem Cells and Neuroregeneration
Neuroimaging, Diagnostics and Disease Treatment
Crossing the Blood Brain Barrier
Demographic Drivers
More People Living Longer
Social Drivers
The Lifestyle Improvement Market
Medical Tourism
Economic Drivers
Global Economic Burden of Brain-Related Illness
Rising Health Care Costs
Research Funding
US Government Research Funding
Stem Cell Funding
International Government Research Funding
Foundations Focus on the Brain
Regulatory Trends
World Regulatory Agencies
Global Clinical Trials
Intellectual Property Trends
Global Intellectual Property Protection
Patent Expirations
Patent Activity in the United States

3: Neuropharmaceutical Sector
Neuropharmaceutical Sector Overview
Trends in Neuropharmaceuticals
Spotlight on Big Pharma
Neuropharmaceutical Partnering and Licensing
Neurology Markets and Pipelines
Alzheimer’s Disease (AD)
AAMI and MCI
Epilepsy and Seizure Disorders
Huntington's disease
Migraine
Multiple Sclerosis
Parkinson’s Disease
Sleep Disorders
Restless Legs Syndrome
Stroke
Traumatic Brain Injury
Psychiatry Markets and Pipelines
Addiction
Anxiety Disorders
Attention Disorders
Depressive Disorders
Bipolar Disorder
Obesity
Schizophrenia
Cognitive Impairment Associated with Schizophrenia
Sensory Markets and Pipelines
Pain
Retinal Disorders

4: Stem Cells and Neuroregeneration

Defining Stem Cell Markets and Players
Therapeutics
Drug Discovery Tools
Stem Cell Banking
Stem Cell Approaches
Background
The Science of Transplantion
Controlling Immune Rejection and Infection
Sources and Harvesting of Stem Cells
Embronic Stem Cells
Fetal Stem Cells
Adult Stem Cells
Stimulation of Endogenous Stem Cells
Stem Cells Scientific Hurdles
Markets and Treatments in Development
Alzheimer’s Disease
Amyotrophic Lateral Sclerosis (ALS)
Hearing Loss
Huntington’s Disease (HD)
Multiple Sclerosis (MS)
Parkinson’s Disease
Retinal Disorders
Spinal Cord Injury (SCI)
Stroke
Other CNS Diseases

5: Neurodevice Sector
 Neurodevice Sector Overview
 Neurodevice Markets
 FDA Classification and Approval Process
 Neurodevice Sector Trends
 Neuroprosthetic Devices
 Cochlear Implants
 Retinal Implants
 Motor Prostheses and Brain Computer Interfaces
 Neuromodulation Devices
 Neuromodulation Device Clinical Trials and Recent Approvals
 Deep Brain Stimulation
 Essential Tremor
 Parkinson’s Disease
 Primary Dystonia
 Severe Obsessive Compulsive Disorder
 Treatment-Resistant Depression
 Epilepsy
 Traumatic Brain Injury and Stroke
 Transcranial Magnetic Stimulation (TMS)
 Alzheimer's
 Treatment Resistant Depression
 Migraine
 Spinal Cord Stimulation (SCS)
 Chronic and Neuropathic Pain
 Spinal Cord Injury
 Vagus Nerve Stimulation (VNS)
 Epilepsy
 Treatment-Resistant Depression
 Obesity
 Peripheral Stimulation
 Balance
 Drug Delivery
 Fecal Incontinence
 Foot Drop
 Hypertension
 Migraine
 Neuropathic Pain
 Restless Legs Syndrome
 Sleep Apnea
 Stroke
Urinary Conditions
Gastric Modulation and Obesity
Neurosurgical devices
Neurosurgical Navigation and Equipment
Image Guided Navigation (IGN)
Intraoperative Magnetic Resonance Imaging (iMRI)
Automated Surgical Systems
Brain Monitoring
Temperature Control Systems
Neurovascular Intervention
Ischemic Stroke
Catheters, Stents and Perfusion devices
Retrieval and Protection devices
Ultrasound Thrombolysis
Hemorrhagic Stroke
Coils
Liquid Embolics
Stents
Neurosoftware
Attention Deficit Disorder
Cognition and Aging
Emotional Wellbeing
Learning Disabilities and Autism
Pain

The Neurotechnology Industry 2011 Report: Exhibits, Tables, and Charts
1-1: Number of Individuals Afflicted by Indication, US and Worldwide, Top 15 Indications
1-2: Global Pharmaceutical Sales by Indication, 2010
1-3: Neurotechnology Industry Taxonomy
1-4: Proportion of Patient Population Segmented by Neurotech Market Opportunity
1-5: NASDAQ NeuroInsights Neurotech Index Performance vs. S&P500, NASDAQ Composite, and NASDAQ Biotechnology Index
2-1: Projected Percentage Increase in Global Populations aged 65 and over, 1994-2020
2-7: Selected US Foundations with a Significant focus on Brain Research and Education
2-8: Most Generous Philanthropists for Medical and Brain Research
2-9: Global Stem Cell Policy Map
3-1: Neuropharmaceutical Revenues by Indication (2010)
3-2: FDA Pharmaceutical Approval Process
3-3: Big Pharma neuropharmaceutical revenues
3-4: Neuropharmaceutical Partnering and Licensing Deals 2004-Q1 2011
3-5: Clinical Trials for Alzheimer’s disease (company, compound, phase, mechanism)
3-6: Clinical Trials for AAMI and MCI (company, compound, phase, mechanism)
3-7: Clinical Trials for Epilepsy (company, compound, phase, mechanism)
3-8: Clinical Trials for Huntington’s disease (company, compound, phase, mechanism)
3-9: Clinical Trials for Migraine (company, compound, phase, mechanism)
3-10: Clinical Trials for Multiple sclerosis (company, compound, phase, mechanism)
3-11: Clinical Trials for Parkinson’s disease (company, compound, phase, mechanism)
3-12: Clinical Trials for sleep disorders (company, compound, phase, mechanism)
3-13: Clinical Trials for stroke Treatment (company, compound, phase, mechanism)
3-14: Clinical Trials for traumatic brian injury (company, compound, phase, mechanism)
3-15: Number of People with Addiction and Impulse Control Disorders (WW and US)
3-16: Clinical Trials for addition and substance abuse (company, compound, phase, mechanism)
3-17: Clinical Trials for anxiety disorders (company, compound, phase, mechanism)
3-18: Clinical Trials for ADHD (company, compound, phase, mechanism)
3-19: Clinical Trials for Depressive disorders (company, compound, phase, mechanism)
3-20: Clinical Trials for Obesity Treatment (company, compound, phase, mechanism)
3-21: Clinical Trials for Schizophrenia and psychosis (company, compound, phase, mechanism)
3-22: Clinical Trials for Retinal disorders (company, compound, phase, mechanism)
3-23: Clinical Trials for Nociceptive Pain (company, compound, phase, mechanism)
3-23: Clinical Trials for Neuropathic Pain (company, compound, phase, mechanism)
4-1: FDA Classification and Approval Process for Medical Devices
4-2: Neurodevice Acquisition and Investment Activity: Medtronic, Boston Scientific, J&J
4-3: Neurodevice Markets and Revenues (Neuroprosthetic, Neuromodulation, Neurosurgical, Neurofeedback)
4-4: Neuromodulation Device Clinical Trials
5-1: Neurodiagnostics Markets and Annual Growth (Neuroimaging, In Vitro Diagnostics, Neuroinformatics)
5-2: FDA Approval and Insurance Reimbursement of Diagnostics
5-3: Neuroimaging Technology (CT, MRI, fMRI, PET, SPECT, EEG, MEG)
5-6: Alzheimer’s Disease Neuroimaging Initiative
5-7: Neuroinformatics Data Storage
5-8: Paul Allen Brain Atlas Project and IBM Blue Brain Project
6-1: Total US Venture Capital Investment, 1999-2010
6-2: US Life Science Venture Capital Investment, 1999-2010
6-3: US Neurotechnology Venture Capital Investment, 1999-2010
6-4: Neurotech as Percent of Life Science Venture Investment, 1999-2010
6-5: Top Five Neurotechnology Venture Capital Financings, 2001-2010
6-6: Top 12 Neurotech Venture Capital Firms with Investments
7-1: Neurotechnology Initial Public Offerings US, 2004-Q1 2011
7-2: Selected Neurotech M&A Activity, 2004-Q1 2011
7-3: Neurotech Index Companies 2011
7-4: Neurotech Index Company Fundamentals
7-5: Index Company Performance
8-1 Leading Neurotechnology Research Centers
8-2 Neurotech Research Centers and Affiliated Institutes, Funding, Recent Significant Investments, Reputation, Translation of Discoveries to Industry
8-3: UCSF
8-4: UCLA
8-5: Harvard University
8-6: Stanford University
8-7: MIT
8-8: Columbia University
8-9: Washington University
8-10: University College London
8-11: Karolinska Institute
8-12: RIKEN Brain Science Institute
9-1 NeuroInsights’ Leading Neurotech Nexus Ratings
9-2 Conclusions and Policy Recommendations
10-1 Neuropharmaceutical Companies Private Profiles (status, funding, location, investment, descriptions, investors)
10-2 Neuropharmaceutical Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
10-3 Neurodevice Companies Private Profiles (status, funding, location, investment, descriptions, investors)
10-4 Neurodevice Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
10-5 Neurodiagnostic Companies Private Profiles (status, funding, location, investment, descriptions, investors)
10-6 Neurodiagnostic Companies Public Profiles (status, symbol, HQ, market cap revenues, description)